

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF      Art Unit: 1618  
Pruschy, Martin      Examiner: Gembel, Shirley V  
INTERNATIONAL APPLICATION NO: PCT/EP2004/002610  
FILED: March 12, 2004  
U.S. APPLICATION NO: 10/549978  
35 USC §371 DATE: November 15, 2006  
FOR: Treatment of Proliferative Diseases with Epothilone Derivatives and  
Radiation

MS: Amendment  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ supplemental to the Information Disclosure Statement filed September 6, 2007.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to  
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.  
§1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the  
references cited on the attached form(s) PTO/SB/08A/B.

☒ Copy of the reference is enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initiated PTO/SB/08A/B form(s).

Novartis Pharmaceuticals Corporation  
One Health Plaza, Bldg. 101  
East Hanover, NJ 07936  
(862) 778-7824

Date: June 29, 2011

Respectfully submitted,



George Dohmann  
Attorney for Applicant  
Reg. No. 33,593